Suchergebnisse - "Motoi, Noriko"

PubPharm (12)

1

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Shirasawa, M. | Yoshida, T. | Imabayashi, T. | +13

CommentIn: Eur J Cancer. 2022 May;167:149-151. - PMID 35307255

2

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

enthalten in: Anticancer research | 2021

von Shimoda, Y. | Yoshida, T. | Shirasawa, M. | +11

3

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma

enthalten in: Clinical lung cancer | 2021

von Shirasawa, M. | Yoshida, T. | Takayanagi, D. | +16

4

Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC

enthalten in: Clinical lung cancer | 2021

von Takeyasu, Y. | Yoshida, T. | Shibaki, R. | +7

5

Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment

enthalten in: Japanese journal of clinical oncology | 2021

von Nishida, T. | Matsumoto, Y. | Sasada, S. | +6

6

Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2020

von Shirasawa, M. | Yoshida, T. | Matsumoto, Y. | +8

7

A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2019

von Naito, T. | Udagawa, H. | Sato, J. | +15

8

Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease

enthalten in: Medical oncology (Northwood, London, England) | 2019

von Shibaki, R. | Murakami, S. | Matsumoto, Y. | +9

9

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer

enthalten in: Thoracic cancer | 2019

von Shibaki, R. | Murakami, S. | Shinno, Y. | +8

10

Programmed Death-Ligand 1 Immunohistochemistry Testing : A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Büttner, R. | Gosney, J. | Skov, B. | +11

CommentIn: J Thorac Dis. 2018 Mar;10 (3):1217-1219. - PMID 29708172